Strides Shasun’s wholly owned subsidiary Strides Pharma Global Pte. Ltd has got green signal from the US Food and Drug Administration, for Tenofovir Disoproxil Fumarate tablets, 300 mg.
Tenofovir Disoproxil Fumarate tablet is suggested in combination with other antiretroviral agents for treatment of HIV-1 infection in adults and also for the treatment of chronic hepatitis B in adults.
As per Strides, the product will be manufactured at its oral dosage facility at Bangalore and it will be marketed by Strides Pharma Inc in the US market.
Furthermore, the product which has received approval is a generic version of Gilead’s Viread tablet. The company will launch the product immediately, as it has got tentative approval from USFDA for supplying under US President’s Emergency Plan for AIDS Relief program.
